Evolocumab
- Generic Name
- Evolocumab
- Brand Names
- Repatha
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1256937-27-5
- Unique Ingredient Identifier
- LKC0U3A8NJ
- Background
Evolocumab is a monoclonal antibody designed for the treatment of hyperlipidemia by Amgen. It is a subcutaneous injection approved by the FDA for individuals on maximum statin therapy who still require additional LDL-cholesterol lowering. It is approved for both homozygous and heterozygous familial cholesterolemia as an adjunct to other first-line therapies....
- Indication
Evolocumab is indicated in adult patients with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization. It is also indicated as an adjunct to diet, alone or in combination with other hypolipidemic treatments, in adults with primary hyperlipidemia (and in pediatric patients ≥10 years old with hete...
- Associated Conditions
- Coronary Revascularization, Myocardial Infarction, Stroke, Increases in serum total low-density lipoprotein (LDL)
- Associated Therapies
- -
Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Registration Number
- NCT04303377
- Locations
- 🇮🇹
IRCCS Policlinico San Matteo, Pavia, PV, Italy
PCSK9 Inhibitor Treatment for Patients With SPG5
- First Posted Date
- 2019-09-24
- Last Posted Date
- 2021-11-23
- Target Recruit Count
- 30
- Registration Number
- NCT04101643
- Locations
- 🇨🇳
Department of Neurology , First Affiliated Hospital Fujian Medical University, Fuzhou, China
Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2019-09-24
- Last Posted Date
- 2020-11-24
- Lead Sponsor
- Tianjin Chest Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT04100434
- Locations
- 🇨🇳
Tianjin Chest Hospital,, Tianjin, China
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With High Risk Coronary Artery Disease (FORWARD)
- Conditions
- Interventions
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- Beijing Anzhen Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT04087915
- Locations
- 🇨🇳
Beijing Anzhen Hospital, Capital Medical University, Beijing, Beijing, China
Evolocumab in Patients With Acute MI
- First Posted Date
- 2019-09-09
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 100
- Registration Number
- NCT04082442
- Locations
- 🇺🇸
The Johns Hopkins Hospital, Baltimore, Maryland, United States
Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH
- Conditions
- Interventions
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- LIB Therapeutics LLC
- Target Recruit Count
- 65
- Registration Number
- NCT04034485
- Locations
- 🇮🇱
Department of Medicine, Hadassah University Hospital, Jerusalem, Israel
🇿🇦Division of Lipidology, Department of Medicine University of Cape Town, Cape Town, Western Province, South Africa
🇹🇷Ege University Medical School, İzmir, Bornova, Turkey
Impact of Evolocumab in Cardiac Transplant Patients With CAV
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 26
- Registration Number
- NCT03944577
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery
- Conditions
- Interventions
- First Posted Date
- 2019-04-02
- Last Posted Date
- 2020-07-13
- Lead Sponsor
- Unity Health Toronto
- Target Recruit Count
- 766
- Registration Number
- NCT03900026
- Locations
- 🇺🇸
Jacksonville Center for Clinical Research, Jacksonville, Florida, United States
🇨🇦Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦University of Alberta, Edmonton, Alberta, Canada
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
- Conditions
- Interventions
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 12301
- Registration Number
- NCT03872401
- Locations
- 🇺🇸
Nature Coast Clinical Research LLC, Crystal River, Florida, United States
🇺🇸Multicare Institute for Research and Innovation, Puyallup, Washington, United States
🇦🇺Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
Evolocumab for PCSK9 Lowering in Early Acute Sepsis (The PLEASe Study)
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 36
- Registration Number
- NCT03869073
- Locations
- 🇨🇦
Surrey Memorial Hospital, Surrey, British Columbia, Canada
🇨🇦Vancouver General Hospital, Vancouver, British Columbia, Canada
🇨🇦St. Paul's Hospital, Vancouver, British Columbia, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.